Pulse Biosciences raised $20 million in an initial public offering this week after floating 5 million shares at $4 apiece, for a fully diluted valuation of $51 million. Burlingame, Calif.-based Pulse is developing “nano-pulse electro-signaling,” in which extremely short-duration pulsed electrical fields are directed at solid tumors. It’s designed to induce a type of programmed cell death […]
Radiosurgery/Radiation therapy
Sensus Healthcare scales back planned IPO
Sensus Healthcare last week said it plans to scale back its planned initial public offering, after tabling the flotation earlier this year. Boca Raton, Fla.-based Sensus makes the SRT-100 and SRT-100 Vision photon X-ray low-energy superficial radiotherapy systems for treating non-melanoma skin cancers, including basal cell and squamous cell carcinomas. The company said March 9 that it planned […]
Varian backs Phase III non-small cell lung cancer trial
Varian Medical (NYSE:VAR) said today it is supporting a Phase III clinical trial set to compare outcomes of radiosurgery against surgical resection for treating early-stage, high-risk operable non-small cell lung cancer. The randomized “Stablemates Trial” will test the hypothesis that 3-year overall survival in high risk operable patients with Stage I NSCLC is equivalent or greater in […]
IsoRay spikes GliaSite radiation therapy device
IsoRay (NYSE:ISR) said yesterday that it’s spiking its GliaSite radiation therapy system for treating brain cancers, after achieving only modest sales since the FDA cleared the device in 2011. Richland, Wash.-based IsoRay said it’s cancelling its deals with Dr. Reddy’s Laboratories (NYSE:RDY), Hologic (NSDQ:HOLX) and Karlheinz Goehl-Medizintechnik Goehl concerning GliaSite. “The GliaSite product has resulted in only marginal […]
Sensus Healthcare sets terms on $20m IPO
Sensus Healthcare yesterday set the terms on an initial public offering that would raise $20 million at the mid-point. Boca Raton, Fla.-based Sensus makes the SRT-100 and SRT-100 Vision photon X-ray low-energy superficial radiotherapy systems for treating non-melanoma skin cancers, including basal cell and squamous cell carcinoma. Sensus said it plans to float more than 1.8 million […]
Advanced Medical Isotope hires IR firm Circadian Group
Advaned Medical Isotope Corp said Wednesday it hired medical device, pharma and biotech-focused investor relations firm Circadian Group. Newly-retained Circadian group will focus on presenting AMIC’s past success, current corporate profile and future catalysts to potential international investors. “Circadian Group is an excellent fit for AMIC. Circadian’s expertise in our industry at our stage of development, […]
Lantheus sells Canadian radiopharmacy biz for $9m
Lantheus Medical Imaging said yesterday it sold its radiopharmacy and Canadian Gludef manufacturing and distribution businesses to Isologic Radiopharmaceuticals for $9m. As part of the sale, Lantheus and Isologic inked a long-term supply deal which positions Lantheus to supply Isologic with its products on commercial terms, with a set of product purchase commitments included. “We […]
Brain cancer: NovoCure looks to get 2nd-gen Optune device on the U.S. market
NovoCure (NSDQ:NVCR) said today that it applied for a supplemental pre-market approval from the FDA for the 2nd generation of its Optune device for treating glioblastoma, a form of brain cancer. The FDA approved Optune’s 1st iteration in April 2011. It’s a mobile device that delivers low-intensity, intermediate frequency, alternating electric fields, referred to as “tumor treating fields,” […]
Perseon slashes workforce after $11m merger fails
Perseon Medical (NSDQ:PRSN) said yesterday that it laid off a “substantial” number of employees as it looks to stay afloat after the failure last month of an $11 million merger with Galil Medical. Salt Lake City-based Perseon, formerly known as BSD Medical, makes the MicroThermX microwave ablation device. The Galil merger, announced in October, foundered after not enough stockowners tendered […]
Qfix wins FDA 510(k) for SRS immobilization device
Radiotherapy patient positioning device manufacturer Qfix said today it won FDA 510(k) clearance for its Encompass stereotactic radiosurgery immobilization system. The Encompass imobilization system uses posterior thermoplastic and an anterior open view mask that is compatible with optical tracking systems to allow for sub-millimeter accuracy and immobilization during stereotactic radiosurgery, the Avondale, Penn.-based company said. […]
Edap slips shareholders lawsuit
Edap (NSDQ:EDAP) said yesterday that the appeal deadline lapsed for a shareholders lawsuit filed after an FDA advisory panel recommended against approval for its its Ablatherm device for treating prostate cancer. EDAP shares plunged last year after the FDA’s Gastroenterology & Urology Devices panel voted that the device did not appear to be effective or safe. Ablatherm, which won […]